Development of sustained release formulation of an antithrombotic drug and application of fuzzy logic

Pharmaceutical Development and Technology

Volumn 17, Issue 2, 2012, Pages 242-250

  Tan, Celil ^a   Degim, Ismail Tuncer ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Antithrombotic drug; Artificial neural network modelling; Clopidogrel; Fuzzy logic; Modelling; Sustained release

Indexed keywords

CLOPIDOGREL;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG MARKETING; DRUG SOLUBILITY; FUZZY LOGIC; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; POWDER; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TABLET COMPRESSION; TABLET FORMULATION;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; DELAYED-ACTION PREPARATIONS; FUZZY LOGIC; NEURAL NETWORKS (COMPUTER); PLATELET AGGREGATION INHIBITORS; PROTHROMBIN TIME; RABBITS; SOLUBILITY; TICLOPIDINE;

EID: 84857415911     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.531739     Document Type: Article

References (32)

1. Accessed from the website: http://en.wikipedia.org/wiki/ Clopidogrel
2. Lenz TL, Wilson A. Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. Clin Pharmacokinet 2003;42:909-920.
3. Kam PCA, Nethery CM. The Thinopyridine derivatives (platel adenosine diphosphate receptor antagonist), pharmacology and clinical developments. Anaesthesia 2003;58:28-35.
4. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metabolism Disposit 2002;30:1258-1295.
5. Herbert JM, Frechel D, Vallee E, Kieffer G, Gouy D, Berger Y. Clopidogrel, a novel antithrombotic agent. Cardiovasc Drug Rev 1993;11:180-198.
6. Mikatos A, Panderi I. Determination of the carboxylic acid metabolite of clopidogrel in human plasma by liquid chromatography-electrospray ionization mass spectrometry. Analyt Chimica Acta 2004;505:107-114.
7. Accessed from the website: http://www.fda.Gov/Medwatch/ safety/2004/Oct-PI/Plavix-PI.Pdf: (2006).
8. Mcewen J, Strauch G, Perle SP, Al E. Clopidogrel bioavailability is unaffected by food or antiacids. British Journal of Clinical Pharmacology 1996;36:856.
9. Ksycinska H, Rudzki P, Bukowska-Kiliszek M. Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. J Pharm Biomed Anal 2002;28:431-438.
10. Garnier J, Cric S, Curry J, Morelli G, Arseneault A, Tanguay M. The single-dose pharmacokinetics of clopidogrel in healthy adult volunteers. Clin Pharmacol & Therapeutics 2003;73:2.
11. Lainesse A, Ozalp Y, Wong H, Alpan RS. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneim-Forsch/Drug Res 2004;54 No.9a:600-604.
12. Taubert D, Kastrati A, Bevkerath HV, Schomig A, Schomig E, Pogatsa-Murray G. Absorbption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Circulation 2005;8:2946-2950.
13. Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharmaceut Biomed Anal 2008;48:1219-1224.
14. Ki MH, Choi MH, Ahn KB, Kim BS, Im DS, Ahn SK, et al. The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. Arch Pharm Res 2008;31:250-258.
15. USPTO Patent Application #: 20070003628: Nanoparticulate clopidogrel formulations.
16. Podczeck F, Newton JM. Powder and capsule filling properties of lubricated granulated cellulose powder. Eur J Phar Biol 2000;50:373-377.
17. Picker-Freeyer KM, Brink D. Evaluation of powder and tableting properties of chitosan. AAPS Pharmscitech 2006;7(3):E1-10.
18. Schussele A, Bauer-Brandl A. Note on the measurement of flowability according to the European pharmacopoeia. Int J Phar 2003;257:301-304.
19. Kumar V, Kothari SH, Banker GS. Compression, compaction, and disintegration properties of low crystallinity celluloses produced using different agitation rates during their regeneration from phosphoric acid solutions. AAPS Pharmscitech 2001;2(2):1-7.
20. Taubert D, Kastrati A, Harlfinger S, Gorchakva O, Lazar A, Bevkerath HV, et al. Pharmacokinetics of clopidogre after administration of a high loading dose. Thromb Haemost 2004;92:311-316.
21. Walsh P. Physicians' Desk Reference (2005) Medical Economics Company, USA.
22. Mikatos A, Panderi I. A validated LC method for the determination of clopidogrel in pharmaceutical preparations. J Pharm Biomed Anal 2002;28:431-438.
23. Sproule BA, Naranja CA, Türksen IB. Fuzzy pharmacology: Theory and applications. Trends Pharmacolog Sci 2002;23(9):412-417.
24. Brier ME, Zurada JM, Aronoff GR. Neural network predicted peak and trough gentamicin concentrations. Pharm Res 1995;12:406-412.
25. Veng-Pedersen P, Modi NB. Application of neural networks to pharmacodynamics. J Pharm Sci 1993;82:918-926.
26. Huuskonen J, Salo M, Taskinen J. Neural network modeling for estimation of the aqueous solubility of structurally related drugs. J Pharm Sci 1997;86:450-454.
27. Bourquin J, Schmidli H, Van-Hoogevest P, Leuenberger H. Basic concepts of artificial neural networks (ANN) modeling in the application to pharmaceutical development. Pharm Dev Technol 1997;2:95-109.
28. Baxt WG. Application of artificial neural networks to clinical medicine. Lancet 1995;346:1135-1138.
29. Bozic DZ, Vrecer F, Kozjek F. Optimization of diclofenac sodium dissolution from sustained release formulations using an artificial neural network. Eur J Phar Sci 1997;5:163-169.
30. Takahara J, Takayama K, Nagai T. Multi-objective simultaneous optimization technique based on an artificial neural network in sustained release formulations. J Cont Rel 1997;49:11-20.
31. Chen Y, McCall TW, Baichwal AR, Meyer MC. The applications of an artificial neural network and pharmacokinetics simulations in the designing of controlled-release dosage forms. J Cont Rel 1999;59:33-41.
32. Grau AJ, Reiners S, Lincy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke. Stroke 2003;April:849-855.